Insulatard

Insulin Human, the active ingredient in Insulatard, is a recombinant human insulin classified as an intermediate‑acting insulin presented as an injectable suspension for subcutaneous administration. It is used to lower elevated blood glucose levels in patients with diabetes mellitus, providing basal insulin support for both type 1 and type 2 diabetes.

GNH USA supplies Insulatard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled shipments that meet regulatory standards across multiple markets and providing dedicated technical support for product handling.

Insulatard is an intermediate‑acting insulin used in the management of diabetes mellitus and related insulin‑deficiency conditions.

- Type 1 diabetes mellitus: provides basal insulin to maintain fasting glucose levels. - Type 2 diabetes mellitus: used as basal insulin when oral agents no longer achieve target glycaemia. - Insulin deficiency states: supplies exogenous insulin to replace absent endogenous insulin and prevent hyperglycaemia.

Insulatard may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Hypoglycaemia: low blood sugar episodes, especially if meals are missed or dosing is excessive. - Injection site reactions: redness, swelling or itching at the injection site. - Weight gain: increased caloric storage associated with improved glucose utilisation. - Edema: peripheral fluid accumulation, often mild.

Serious or Rare Side Effects: - Severe hypoglycaemia leading to seizures or loss of consciousness. - Allergic reactions: urticaria, angio‑edema or anaphylaxis. - Insulin antibody formation: may alter insulin action and cause unpredictable glucose control.

When using Insulatard, clinicians and patients should observe several safety measures.

- Blood glucose monitoring: check levels regularly to adjust dose and avoid hypoglycaemia. - Dose adjustment during illness: reduce or increase dose based on carbohydrate intake and stress response. - Avoid use in active hypoglycaemia: do not administer if blood glucose is already low. - Caution in renal or hepatic impairment: impaired clearance may increase insulin effect. - Pregnancy and lactation: use only if benefits outweigh potential risks; consult a specialist. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the suspension.

Insulatard can interact with several drug classes, influencing glucose control.

Major Interactions (Avoid): - Sulfonylureas: combined effect may cause severe hypoglycaemia. - Meglitinides: additive glucose‑lowering effect increases hypoglycaemia risk. - Beta‑blockers: may mask hypoglycaemia symptoms, complicating detection.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance insulin sensitivity, requiring dose review. - Thiazide diuretics: can raise blood glucose, potentially reducing insulin efficacy. - Corticosteroids: increase glucose production, possibly necessitating higher insulin doses.